➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Dow
Merck
Mallinckrodt
Baxter

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PF-06649751


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for PF-06649751?

PF-06649751 is an investigational drug.

There have been 10 clinical trials for PF-06649751. The most recent clinical trial was a Phase 1 trial, which was initiated on January 6th 2020.

The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are Pfizer, Cerevel Therapeutics, LLC, and [disabled in preview].

There are ten US patents protecting this investigational drug and seventy-six international patents.

Recent Clinical Trials for PF-06649751
TitleSponsorPhase
Flexible-Dose Trial in Early Parkinson's Disease (PD)Cerevel Therapeutics, LLCPhase 3
Fixed-Dose Trial in Early Parkinson's Disease (PD)Cerevel Therapeutics, LLCPhase 3
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor FluctuationsPfizerPhase 2

See all PF-06649751 clinical trials

Clinical Trial Summary for PF-06649751

Top disease conditions for PF-06649751
Top clinical trial sponsors for PF-06649751

See all PF-06649751 clinical trials

US Patents for PF-06649751

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06649751   Start Trial Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY)   Start Trial
PF-06649751   Start Trial Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (New York, NY)   Start Trial
PF-06649751   Start Trial 1,5-naphthyridine derivatives and MELK inhibitors containing the same OncoTherapy Science, Inc. (Kanagawa, JP)   Start Trial
PF-06649751   Start Trial Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY)   Start Trial
PF-06649751   Start Trial Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY)   Start Trial
PF-06649751   Start Trial 1,5-naphthyridine derivatives and MELK inhibitors containing the same OncoTherapy Science, Inc. (Kanagawa, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06649751

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06649751 Argentina 096748 2033-06-27   Start Trial
PF-06649751 Australia 2014300673 2033-06-27   Start Trial
PF-06649751 Brazil 112015030101 2033-06-27   Start Trial
PF-06649751 Canada 2916653 2033-06-27   Start Trial
PF-06649751 Chile 2015003735 2033-06-27   Start Trial
PF-06649751 China 105324376 2033-06-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Medtronic
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.